600196 复星医药
已收盘 11-14 15:00:00
资讯
新帖
简况
每周股票复盘：复星医药（600196）控股子公司药品获美FDA批准
证券之星 · 02:17
每周股票复盘：复星医药（600196）控股子公司药品获美FDA批准
复星医药(600196.SH)控股子公司药品获美国FDA注册批准
智通财经 · 11-14 17:06
复星医药(600196.SH)控股子公司药品获美国FDA注册批准
复星医药子公司复宏汉霖宣布地舒单抗BILDYOS 和BILPREVDA 获英国批准上市
复星医药官微 · 11-12
复星医药子公司复宏汉霖宣布地舒单抗BILDYOS 和BILPREVDA 获英国批准上市
与复星医药“分手”后，真实生物第三次冲击港股IPO
深圳商报 · 11-11
与复星医药“分手”后，真实生物第三次冲击港股IPO
复星医药（600196）股东上海复星高科技(集团)有限公司质押2000万股，占总股本0.75%
证券之星 · 11-08
复星医药（600196）股东上海复星高科技(集团)有限公司质押2000万股，占总股本0.75%
复星医药（600196）披露为控股子公司提供担保的进展公告，11月06日股价上涨1.21%
证券之星 · 11-06
复星医药（600196）披露为控股子公司提供担保的进展公告，11月06日股价上涨1.21%
复星医药(02196)合计授出453.51万份A股期权
智通财经 · 11-04
复星医药(02196)合计授出453.51万份A股期权
复星医药发布2025年三季报：创新成果持续兑现，前三季度创新药品收入超67亿元
中国医药物资协会 · 11-03
复星医药发布2025年三季报：创新成果持续兑现，前三季度创新药品收入超67亿元
山河药辅最新公告：股东复星医药拟减持不超3.00%股份
证券之星 · 10-31
山河药辅最新公告：股东复星医药拟减持不超3.00%股份
又一例“A拆H”！复星医药拟分拆旗下成都疫苗企业赴港上市
红星资本局 · 10-31
又一例“A拆H”！复星医药拟分拆旗下成都疫苗企业赴港上市
港股异动 | 复星医药(02196)盘中涨近4% 前三季度归母净利同比增加25.5% 公司持续推进创新品上市
智通财经 · 10-31
港股异动 | 复星医药(02196)盘中涨近4% 前三季度归母净利同比增加25.5% 公司持续推进创新品上市
复星医药前3季营收扣非净利双降 靠出售资产拉升净利
中金财经 · 10-30
复星医药前3季营收扣非净利双降 靠出售资产拉升净利
复星医药拟分拆旗下疫苗企业复星安特金赴港上市
新京报 · 10-29
复星医药拟分拆旗下疫苗企业复星安特金赴港上市
AI无界，智绘新篇 | 方舟健客(06086)战略携手复星医药(02196)，共创银屑病管理数智新生态
智通财经 · 10-29
AI无界，智绘新篇 | 方舟健客(06086)战略携手复星医药(02196)，共创银屑病管理数智新生态
群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元
智通财经 · 10-29
群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元
前三季度营收扣非下滑 复星医药靠出售资产拉升净利 拟分拆亏损子公司赴港上市
滚动播报 · 10-28
前三季度营收扣非下滑 复星医药靠出售资产拉升净利 拟分拆亏损子公司赴港上市
复星医药 - 批准复星安吉维生物医药拟在香港证券交易所分拆上市的计划
美股速递 · 10-28
复星医药 - 批准复星安吉维生物医药拟在香港证券交易所分拆上市的计划
复星医药最新公告：拟筹划控股子公司复星安特金于香港联交所上市
证券之星 · 10-28
复星医药最新公告：拟筹划控股子公司复星安特金于香港联交所上市
复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%
智通财经 · 10-28
复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%
每周股票复盘：复星医药（600196）召开2025年首次临时股东会
证券之星 · 10-26
每周股票复盘：复星医药（600196）召开2025年首次临时股东会
加载更多
公司概况
公司名称：
上海复星医药(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1998-08-07
主营业务：
上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。
发行价格：
7.15
{"stockData":{"symbol":"600196","market":"SH","secType":"STK","nameCN":"复星医药","latestPrice":28.82,"timestamp":1763103601000,"preClose":28.88,"halted":0,"volume":20981267,"delay":0,"changeRate":-0.0021,"floatShares":2118000000,"shares":2670000000,"eps":1.2293,"marketStatus":"已收盘","change":-0.06,"latestTime":"11-14 15:00:00","open":28.72,"high":29.13,"low":28.65,"amount":608000000,"amplitude":0.0166,"askPrice":28.83,"askSize":344,"bidPrice":28.82,"bidSize":397,"shortable":0,"etf":0,"ttmEps":1.2293,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763343000000},"marketStatusCode":5,"adr":0,"adjPreClose":28.88,"symbolType":"stock","openAndCloseTimeList":[[1763083800000,1763091000000],[1763096400000,1763103600000]],"highLimit":31.77,"lowLimit":25.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":2670429325,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":23.444237,"roe":"5.3%","epsLYR":1.04,"committee":0.243885,"marketValue":76962000000,"turnoverRate":0.0099,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2025-11-17。","hkstockBrief":{"symbol":"02196","market":"HK","secType":"STK","nameCN":"复星医药","latestPrice":23.14,"timestamp":1763107691006,"preClose":23.08,"halted":0,"volume":3794000,"delay":0,"premium":"-26.62"},"floatMarketCap":61055000000},"requestUrl":"/m/hq/s/600196","defaultTab":"news","newsList":[{"id":"2583659958","title":"每周股票复盘：复星医药（600196）控股子公司药品获美FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583659958","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583659958?lang=zh_cn&edition=full","pubTime":"2025-11-16 02:17","pubTimestamp":1763230632,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，复星医药报收于28.82元，较上周的28.23元上涨2.09%。本周，复星医药11月14日盘中最高价报29.13元。本周关注点公司公告汇总：复星医药控股子公司复宏汉霖自主研发的帕妥珠单抗注射液获美国FDA批准上市。复宏汉霖已将该产品在美国等地区的商业化权利授予Organon LLC，将依据协议获得销售里程碑款及销售提成。截至2025年10月，该产品累计研发投入约2.25亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0012","BK1515","BK0175","BK1593","600196","BK0239","BK0060","BK1191","02196","BK0028","BK0187","BK0183","BK0096","BK0188"],"gpt_icon":0},{"id":"2583576177","title":"复星医药(600196.SH)控股子公司药品获美国FDA注册批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2583576177","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583576177?lang=zh_cn&edition=full","pubTime":"2025-11-14 17:06","pubTimestamp":1763111217,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的POHERDY1注射液的生物制品许可申请获美国FDA批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0060","BK0028","BK0196","BK1515","02196","BK0096","BK0175","BK1191","BK0183","600196","BK0239","BK0188","BK0187","BK1593"],"gpt_icon":0},{"id":"2582932461","title":"复星医药子公司复宏汉霖宣布地舒单抗BILDYOS 和BILPREVDA 获英国批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2582932461","media":"复星医药官微","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582932461?lang=zh_cn&edition=full","pubTime":"2025-11-12 17:36","pubTimestamp":1762940160,"startTime":"0","endTime":"0","summary":"中国上海，2025年11月11日——复星医药子公司复宏汉霖（2696.HK）宣布，英国药品和健康产品管理局（MHRA）已批准地舒单抗注射液（60 mg/mL）BILDYOS （denosumab）和地舒单抗注射液（120mg/ ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251112/c672428158.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0175","BK0183","BK0188","BK0239","BK0028","BK0196","BK0012","BK0060","BK0187","600196","BK0096"],"gpt_icon":0},{"id":"2582331338","title":"与复星医药“分手”后，真实生物第三次冲击港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2582331338","media":"深圳商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582331338?lang=zh_cn&edition=full","pubTime":"2025-11-11 12:45","pubTimestamp":1762836300,"startTime":"0","endTime":"0","summary":"据港交所披露，真实生物科技有限公司近日递表交港交所主板，中金公司为其独家保荐人。这是公司第三次在港交所申请上市，此前曾在2022年8月、2025年2月递表过港交所，但最终无果。资料显示， ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251111/c672391030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0028","BK0060","BK0239","BK0187","BK0196","BK0188","BK0012","BK0175","BK0096","BK0183","600196"],"gpt_icon":0},{"id":"2581880404","title":"复星医药（600196）股东上海复星高科技(集团)有限公司质押2000万股，占总股本0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581880404?lang=zh_cn&edition=full","pubTime":"2025-11-08 00:23","pubTimestamp":1762532604,"startTime":"0","endTime":"0","summary":"证券之星消息，复星医药11月8日公开信息显示，股东上海复星高科技(集团)有限公司向中国工商银行股份有限公司上海市长宁支行合计质押2000.0万股，占总股本0.75%。质押详情见下表：截止本公告日，股东上海复星高科技(集团)有限公司已累计质押股份5.47亿股，占其持股总数的61.46%。复星医药主营业务：制药、医疗器械与医学诊断、医疗健康服务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110800000751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0187","600196","BK0175","BK0183","BK0060","BK0012","BK1515","BK0239","BK1593","02196","BK0188","BK0196","BK1191","BK0028"],"gpt_icon":0},{"id":"2581091141","title":"复星医药（600196）披露为控股子公司提供担保的进展公告，11月06日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091141","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581091141?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:14","pubTimestamp":1762438463,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，复星医药报收于28.49元，较前一交易日上涨1.21%，最新总市值为760.81亿元。公司近日发布公告称，上海复星医药（集团）股份有限公司为控股子公司复星医药产业、复星安特金、复星健康及复星曜泓（西藏）提供担保，担保金额分别为20,000万元、30,000万元、20,000万元和32,000万元。截至2025年11月6日，集团实际对外担保余额约2,354,378万元，占2024年末经审计净资产的49.82%，无逾期担保。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0183","BK0012","BK1191","BK0175","600196","BK1515","02196","BK0096","BK0028","BK0060","BK0196","BK0188","BK0239","BK1593"],"gpt_icon":0},{"id":"2580871337","title":"复星医药(02196)合计授出453.51万份A股期权","url":"https://stock-news.laohu8.com/highlight/detail?id=2580871337","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580871337?lang=zh_cn&edition=full","pubTime":"2025-11-04 19:14","pubTimestamp":1762254840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)公布，鉴于2025 年 A 股股票期权激励计划所确定的首次授予拟激励对象中的6名已不在集团任职、不再属于本次激励计划的激励对象范围，根据股东会授权，经董事会批准、董事会薪酬与考核委员会核查，对首次授予的拟激励对象名单及所涉A股期权数量进行调整：即首次授予的拟激励对象由201名调整为195 名、首次授予的A股期权数量由458.09万份调整为453.51万份。2025年11月4日，合计453.51万份A股期权已授予195名激励对象，行权价格为人民币27.93元/股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","BK0175","BK1191","BK1593","BK1515","BK0239","BK0012","600196","159982","BK0187","02196","399300","BK0060","BK0188","BK0196","BK0096","BK0028"],"gpt_icon":0},{"id":"2580129167","title":"复星医药发布2025年三季报：创新成果持续兑现，前三季度创新药品收入超67亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2580129167","media":"中国医药物资协会","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580129167?lang=zh_cn&edition=full","pubTime":"2025-11-03 18:39","pubTimestamp":1762166340,"startTime":"0","endTime":"0","summary":"10月28日，中国医药物资协会会长单位复星医药公布2025年三季报。2025年前三季度，复星医药实现营业收入人民币293.93亿元、归母净利润25.23亿元，同比增长25.5%。创新药品收入稳健增长，2025年前三季度创新药品收入超67亿元，同比增长18.09%，收入结构持续优化。2025年前三季度，经营活动产生的现金流量净额为33.82亿元，同比增长13.23%，经营质量持续提升。研发投入方面，2025年前三季度，复星医药研发投入共计39.98亿元，同比增长2.12%；其中研发费用27.30亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-11-03/doc-infwcqvf5433034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","BK0012","BK0239","BK1191","BK1593","BK1515","BK0096","BK0196","BK0188","BK0175","02196","BK0060","BK0028","BK0183","600196"],"gpt_icon":0},{"id":"2579616314","title":"山河药辅最新公告：股东复星医药拟减持不超3.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2579616314","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579616314?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:19","pubTimestamp":1761913166,"startTime":"0","endTime":"0","summary":"山河药辅(300452.SZ)公告称，持股9.23%的股东上海复星医药产业发展有限公司因自身资金需求，计划以集中竞价交易和大宗交易方式合计减持不超过697.87万股，占公司总股本的3.00%。减持期间为公告发布之日起15个交易日后的90日内（2025年11月24日至2026年2月21日）。在任意连续90日内，大宗交易减持不超过公司总股本的2%（465.25万股），集中竞价交易减持不超过公司总股本的1%（232.62万股）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100046099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0177","BK0028","02196","BK1593","BK0012","BK0196","BK0183","BK0188","BK1191","BK0060","BK0239","BK0096","BK0175","BK1515","600196","300452"],"gpt_icon":0},{"id":"2579598934","title":"又一例“A拆H”！复星医药拟分拆旗下成都疫苗企业赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2579598934","media":"红星资本局","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579598934?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:03","pubTimestamp":1761901380,"startTime":"0","endTime":"0","summary":" 10月28日晚，复星医药发布公告称，为更好地促进集团旗下具备一定细分行业平台能力的控股子公司企业管治水平持续提升和稳健可持续发展，从而实现股东价值最大化，公司拟筹划分拆控股子公司复星安特金（成都）生物制药有限公司于香港联交所上市。复星医药产业拟现金出资人民币1亿元认缴目标基金中的等值财产份额，占比10%。目标基金设立后，将成为复星医药联营企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-10-31/doc-infvupat5654318.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0183","BK1191","BK1593","BK0012","BK0175","BK0196","BK0096","159646","600196","BK0028","BK0188","BK0239","BK0187","02196","BK1515","BK0060"],"gpt_icon":0},{"id":"2579892134","title":"港股异动 | 复星医药(02196)盘中涨近4% 前三季度归母净利同比增加25.5% 公司持续推进创新品上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2579892134","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579892134?lang=zh_cn&edition=full","pubTime":"2025-10-31 10:10","pubTimestamp":1761876604,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药盘中涨近4%，截至发稿，涨3.76%，报23.16港元，成交额5041.21万港元。消息面上，近日，复星医药发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%；归属于上市公司股东的净利润25.23亿元，同比增加25.5%；基本每股收益0.95元。公告称，2025年前三季度利润总额及归属于上市公司股东的净利润、基本及稀释每股收益同比增加，主要系出售和睦家剩余权益以及其他非核心资产的收益贡献。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1363479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0183","BK0012","BK1191","BK0175","600196","BK1515","02196","BK0096","BK0028","BK0060","BK0196","BK0188","BK0239","BK1593"],"gpt_icon":0},{"id":"2579816341","title":"复星医药前3季营收扣非净利双降 靠出售资产拉升净利","url":"https://stock-news.laohu8.com/highlight/detail?id=2579816341","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579816341?lang=zh_cn&edition=full","pubTime":"2025-10-30 11:08","pubTimestamp":1761793689,"startTime":"0","endTime":"0","summary":"2024年，复星安特金实现营业收入人民币9,742万元、净利润人民币-12,339万元；2025年1至6月，复星安特金实现营业收入人民币15,316万元、净利润人民币-5,845万元。 而2025年前三季度扣非净利润同比下降，主要影响因素包括，营业收入同比减少；于2024年第四季度由合营企业转为全资子公司的复星凯瑞尚处于投入期，对其持股比例的增加导致归属于上市公司股东亏损相应增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20251030/31750211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02196","600196"],"gpt_icon":1},{"id":"2579861909","title":"复星医药拟分拆旗下疫苗企业复星安特金赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2579861909","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579861909?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:49","pubTimestamp":1761738540,"startTime":"0","endTime":"0","summary":"新京报讯（记者王卡拉）今年以来，国内生物医药企业赴港上市持续火热。10月28日晚间，复星医药发布公告，拟筹划分拆集团疫苗业务平台企业复星安特金（成都）生物制药有限公司（以下简称“复 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251029/c672101795.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251029/c672101795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0060","BK0196","600196","BK0188","BK0175","BK0239","BK0187","BK0012","159646","BK0096","BK0183","BK0028"],"gpt_icon":0},{"id":"2579971580","title":"AI无界，智绘新篇 | 方舟健客(06086)战略携手复星医药(02196)，共创银屑病管理数智新生态","url":"https://stock-news.laohu8.com/highlight/detail?id=2579971580","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579971580?lang=zh_cn&edition=full","pubTime":"2025-10-29 18:43","pubTimestamp":1761734585,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，10月29日“世界银屑病日”到来之际，方舟健客与复星医药战略合作签约仪式在上海隆重举行。图/方舟健客与复星医药达成战略合作银屑病是一项具有慢性、复发性、炎症性等特点的疾病，需要长期规范管理。签约仪式后，方舟健客宣布，“AI+银屑病管理新视野”科普宣传周今日正式启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0096","BK0028","BK0239","600196","BK0187","BK1593","BK0188","02196","BK1515","BK0196","BK0060","BK1247","06086","BK0183","BK0175","BK0012"],"gpt_icon":0},{"id":"2579923979","title":"群益证券：维持复星医药(02196)“买进”评级 目标价26.5港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579923979","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579923979?lang=zh_cn&edition=full","pubTime":"2025-10-29 14:16","pubTimestamp":1761718598,"startTime":"0","endTime":"0","summary":"群益证券主要观点如下：公司业绩公司25Q1-Q3实现营收293.9亿元，录得归母净利润25.2亿元，YOY+25.5%，扣非后归母净利润15.7亿元。集采影响总体营收，创新产品延续较快增长公司2025年前三季度及Q3单季营收均有小幅负增长，主要是仿制药品受到药品集中带量采购续标以及部分地方药品集中带量采购的影响，但前三季度创新药保持较快增长，前三季度创新药收入超67亿，同比增长18.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","02196","600196"],"gpt_icon":0},{"id":"2579894830","title":"前三季度营收扣非下滑 复星医药靠出售资产拉升净利 拟分拆亏损子公司赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2579894830","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579894830?lang=zh_cn&edition=full","pubTime":"2025-10-28 23:30","pubTimestamp":1761665400,"startTime":"0","endTime":"0","summary":" 今年前三季度，复星医药业绩“反差”继续。 前三季度，公司营收293.93亿元，同比下滑4.91%；净利润为25.23亿元，同比增长25.5%；扣非净利润15.73亿元，同比减少14.32%。 而2025年前三季度扣非净利润同比下降，主要影响因素包括，营业收入同比减少；于2024年第四季度由合营企业转为全资子公司的复星凯瑞尚处于投入期，对其持股比例的增加导致归属于上市公司股东亏损相应增加。 同日，复星医药还发布公告，拟分拆旗下疫苗平台赴港上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-10-28/doc-infvnnvc8604462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600196","02196"],"gpt_icon":0},{"id":"1178776711","title":"复星医药 - 批准复星安吉维生物医药拟在香港证券交易所分拆上市的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1178776711","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178776711?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:55","pubTimestamp":1761645309,"startTime":"0","endTime":"0","summary":"复星医药 - 批准复星安吉维生物医药拟在香港证券交易所分拆上市的计划","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0239","BK0060","BK0187","BK0196","BK0096","BK0012","BK0175","600196","BK0183","BK0188"],"gpt_icon":0},{"id":"2578265935","title":"复星医药最新公告：拟筹划控股子公司复星安特金于香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2578265935","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578265935?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:13","pubTimestamp":1761642815,"startTime":"0","endTime":"0","summary":"复星医药(600196.SH)公告称，公司拟筹划分拆控股子公司复星安特金（成都）生物制药有限公司于香港联交所上市，以提升其企业管治水平和市场竞争力，同时深化公司在疫苗领域的布局。目前该分拆上市尚处于初步论证阶段，具体方案尚未确定，存在重大不确定性。分拆上市需获得公司董事会、股东会批准，以及中国证监会备案和相关监管机构的核准。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800030366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0060","02196","BK0239","BK0187","BK1593","BK0196","BK0188","BK0012","BK1191","BK0175","BK1515","BK0096","BK0183","600196"],"gpt_icon":0},{"id":"2578593592","title":"复星医药(02196)发布前三季度业绩，归母净利润25.23亿元 同比增加25.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578593592","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578593592?lang=zh_cn&edition=full","pubTime":"2025-10-28 17:12","pubTimestamp":1761642749,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布截至2025年9月30日止9个月业绩，该集团取得营业收入293.93亿元，同比减少4.91%;归属于上市公司股东的净利润25.23亿元，同比增加25.5%;基本每股收益0.95元。2025年前三季度及本报告期(7–9月)营业收入同比减少，主要受药品集中带量采购续标及部分地方药品集中带量采购开展的影响，但同期创新药品收入稳健增长。2025年前三季度利润总额及归属于上市公司股东的净利润、基本及稀释每股收益同比增加，主要系出售和睦家剩余权益以及其他非核心资产的收益贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1361286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","02196"],"gpt_icon":0},{"id":"2578650037","title":"每周股票复盘：复星医药（600196）召开2025年首次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2578650037","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578650037?lang=zh_cn&edition=full","pubTime":"2025-10-26 04:28","pubTimestamp":1761424088,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，复星医药报收于29.08元，较上周的28.72元上涨1.25%。本周，复星医药10月20日盘中最高价报29.45元。本周关注点公司公告汇总：复星医药召开2025年第一次临时股东会，审议并通过多项股权激励及关联交易议案。复星医药2025年第一次临时股东会决议公告显示，会议由董事长陈玉卿主持，审议通过了全部议案，无否决议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600001196.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK1593","BK0028","02196","BK0096","BK0060","BK0175","BK0188","BK0187","BK1515","BK1191","BK0183","600196","BK0012"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1763273654723,"stockEarnings":[{"period":"1week","weight":0.0209},{"period":"1month","weight":0.0077},{"period":"3month","weight":0.0105},{"period":"6month","weight":0.2137},{"period":"1year","weight":0.0774},{"period":"ytd","weight":0.1732}],"compareEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":0.02},{"period":"3month","weight":0.0795},{"period":"6month","weight":0.185},{"period":"1year","weight":0.1807},{"period":"ytd","weight":0.1906}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海复星医药(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"1998-08-07","address":"上海市普陀区曹杨路510号9楼","registeredCapital":"267042万元","survey":" 上海复星医药(集团)股份有限公司的主营业务是制药、医疗器械与医学诊断、医疗健康服务，并通过参股国药控股覆盖到医药商业领域。公司的主要产品是抗肿瘤及免疫调节核心产品、抗感染核心产品、代谢及消化系统核心产品、心血管系统核心产品、中枢神经系统核心产品、原料药和中间体核心产品。","listedPrice":7.15},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.5","shortVersion":"4.35.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"复星医药,600196,复星医药股票,复星医药股票老虎,复星医药股票老虎国际,复星医药行情,复星医药股票行情,复星医药股价,复星医药股市,复星医药股票价格,复星医药股票交易,复星医药股票购买,复星医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"复星医药(600196)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供复星医药(600196)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}